Description: ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
Home Page: www.prokidney.com
PROK Technical Analysis
2000 Frontis Plaza Blvd.
Winston-Salem,
NC
27103
United States
Phone:
336 999 7028
Officers
| Name | Title |
|---|---|
| Dr. Bruce Culleton M.D. | CEO & Director |
| Dr. Timothy A. Bertram D.V.M., Ph.D. | Founder |
| Mr. James Coulston CPA | Chief Financial Officer |
| Mr. Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer & Secretary |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 91.3172 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-07-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 163 |